TG Therapeutics, Inc. $TGTX Position Increased by Voya Investment Management LLC

Voya Investment Management LLC lifted its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 9.8% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 300,453 shares of the biopharmaceutical company’s stock after acquiring an additional 26,714 shares during the period. Voya Investment Management LLC owned 0.19% of TG Therapeutics worth $11,847,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of the company. Vermillion Wealth Management Inc. bought a new stake in TG Therapeutics in the 4th quarter valued at about $30,000. NBC Securities Inc. lifted its position in TG Therapeutics by 82,300.0% in the 1st quarter. NBC Securities Inc. now owns 824 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 823 shares during the last quarter. Golden State Wealth Management LLC lifted its position in TG Therapeutics by 100.0% in the 1st quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 433 shares during the last quarter. SVB Wealth LLC bought a new stake in TG Therapeutics in the 1st quarter valued at about $37,000. Finally, USA Financial Formulas bought a new stake in TG Therapeutics in the 1st quarter valued at about $57,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

Wall Street Analyst Weigh In

Separately, The Goldman Sachs Group upgraded shares of TG Therapeutics to a “hold” rating and set a $37.00 price objective on the stock in a research report on Thursday, July 10th. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $46.25.

TG Therapeutics Stock Up 0.8%

TG Therapeutics stock opened at $31.99 on Wednesday. The stock has a market cap of $5.08 billion, a price-to-earnings ratio of 86.46 and a beta of 1.88. The company has a current ratio of 3.86, a quick ratio of 2.96 and a debt-to-equity ratio of 0.89. The company’s 50-day moving average price is $32.23 and its two-hundred day moving average price is $35.71. TG Therapeutics, Inc. has a 52 week low of $21.16 and a 52 week high of $46.48.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.15). The company had revenue of $141.15 million for the quarter, compared to analyst estimates of $147.76 million. TG Therapeutics had a net margin of 13.31% and a return on equity of 26.05%. The firm’s quarterly revenue was up 92.1% on a year-over-year basis. During the same period in the previous year, the business posted $0.04 EPS. TG Therapeutics has set its FY 2025 guidance at EPS. On average, analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Insider Activity

In other news, Director Sagar Lonial sold 20,852 shares of TG Therapeutics stock in a transaction that occurred on Thursday, September 11th. The shares were sold at an average price of $32.24, for a total value of $672,268.48. Following the transaction, the director owned 94,061 shares of the company’s stock, valued at $3,032,526.64. The trade was a 18.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 10.64% of the stock is owned by corporate insiders.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.